Lobbying Information
Subject Matters
- Consumer Issues
- Health
- Industry
- Intellectual Property
- Internal Trade
- International Trade
- Science and Technology
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
- Patent Act as it relates to the regulation of intellectual property for therapeutic products
- Patent Act with respect to Canada's Access to Medicines Regime (ss. 21.01-21.09)
Policies or Program
- National Pharmaceuticals Strategy, particularly with respect to Health Canada policies and programs on catastrophic drug coverage, common formulary, pricing and purchasing strategies, and expensive drugs for rare diseases
- Patented Medicines Prices Review Board with respect to decisions on the reporting obligations of patented drug products patentees and guidelines for the regulation of pricing of patented drug products
- Science and Technology Strategy led by Industry Canada, particularly with respect to the life sciences priority under the S&T Strategy
Regulation
- Food and Drugs Act Regulations with respect to Data Protection under C.08.004.
- Food and Drugs Act Regulations, specifically with respect to approval, regulation and life-cycle management of therapeutic products
- Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products and the Patented Medicines (Notice of Compliance) Regulations
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
House of Commons
-
Industry Canada
-
Patented Medicine Prices Review Board (PMPRB)
-
Senate of Canada
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
55 Metcalfe Street - Suite 1220
Ottawa, ON K1P 6L5
Canada
Telephone number:
613-236-0455
Ext.
0
Client representative
Wendy Zatylny, Vice President, Government Affairs
Parent Company Information
Rx&D, Canada's Research-Based Pharmaceutical Companies / Rx&D, Les compagnies de recherche pharmaceutique du Canada is not a subsidiary of any other parent companies.
Coalition Members Information
Rx&D, Canada's Research-Based Pharmaceutical Companies / Rx&D, Les compagnies de recherche pharmaceutique du Canada is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Rx&D, Canada's Research-Based Pharmaceutical Companies / Rx&D, Les compagnies de recherche pharmaceutique du Canada are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Rx&D, Canada's Research-Based Pharmaceutical Companies / Rx&D, Les compagnies de recherche pharmaceutique du Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
CARL BALTARE
|
Public offices held
Business address:
50 O'CONNOR ST.
SUITE 901
OTTAWA, ON K1P 6L2
Canada
Telephone number:
613-783-3438
Fax number:
613-782-2426
Consultant Firm and Address
Firm:
GLOBAL PUBLIC AFFAIRS
Address:
50 O'CONNOR ST. SUITE 901
OTTAWA, ON K1P 6L2
Canada
Telephone number:
613-783-3438
Fax number:
613-782-2426
